Loading
A phase 1/2 trial of TQB2825 in diffuse large b-cell lymphoma, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., now recruiting.
Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma is a phase 1/2 interventional study registered as NCT06829771 by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., with 90 participants planned, started 2025-04-23 and due to reach its primary completion in 2026-05. Interventions recorded: TQB2825 injection +R-CHOP regimen, TQB2825 injection + GemOx. Conditions listed: Diffuse Large B Cell Lymphoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/